Overview
The Mitochondrial Dynamics Dysfunction Hypothesis proposes that an imbalance in mitochondrial fission and fusion processes represents a primary upstream mechanism in Parkinson's disease pathogenesis. This hypothesis integrates genetic risk factors (LRRK2 G2019S, GBA), protein aggregation ([alpha-synuclein](/proteins/alpha-synuclein)), and bioenergetic failure into a unified mechanistic framework. Mitochondria—the cellular powerhouses—continuously undergo fission (division) and fusion (joining) to maintain cellular health, and disruption of this balance is now recognized as a central event in dopaminergic neuron death[2][1].
[1]
Core Hypothesis
In PD, dopaminergic neurons experience a pathological shift toward excessive mitochondrial fission, driven by three convergent mechanisms:
LRRK2 kinase hyperactivation (G2019S mutation) → increased DRP1 phosphorylation at Ser616 → excessive mitochondrial fragmentation[6]
Alpha-synuclein oligomer interaction with mitochondrial outer membrane → disruption of MFN2/OPA1 fusion machinery → fusion impairment[3]
GBA-associated lysosomal dysfunction → impaired mitophagy initiation → accumulation of damaged, fragmented mitochondria[11]This fission-skewed state leads to: fragmented, dysfunctional mitochondrial networks; impaired ATP production below the threshold required for neuronal survival; increased reactive oxygen species (ROS) from damaged electron transport chains; and failure to regenerate a healthy mitochondrial population through fusion[4].
Mechanistic Framework
Normal Mitochondrial Dynamics
Mitochondria continuously undergo fission (division) and fusion (joining) to:
- Mix mitochondrial DNA and proteins, maintaining genetic homogeneity
- Distribute energy capacity throughout extensive neuronal processes (axons, dendrites)
- Remove damaged components via mitophagy, maintaining cellular quality control
- Regenerate functional mitochondria from healthy parents
Mermaid diagram (expand to render)
PD-Altered Dynamics: The Fission-Fusion Imbalance
Mermaid diagram (expand to render)
Molecular Cascade in Detail
Step 1: LRRK2 Hyperactivation (G2019S Mutation)
The LRRK2 G2019S mutation causes constitutive kinase activation, one of the most common genetic causes of familial PD (5-6% of cases) and also found in 1-3% of sporadic cases[13]. Hyperactive LRRK2 phosphorylates DRP1 at Ser616 (the fission-promoting site), increasing DRP1 recruitment to the mitochondrial outer membrane and enhancing GTPase activity[1]. The result is excessive mitochondrial fission that generates small, fragmented mitochondria unable to meet the high energy demands of dopaminergic neurons.
Step 2: Alpha-Synuclein Membrane Interaction
Alpha-synuclein (α-Syn) oligomers localize to mitochondria in PD, binding directly to mitochondrial outer membrane proteins including TOM20, disrupting the mitochondrial protein import machinery[14]. α-Syn oligomers also disrupt mitochondrial membrane potential, impair the integrity of the outer mitochondrial membrane, and affect the proper localization of fusion machinery (MFN2, OPA1)[3]. The result is a fusion defect—mitochondria cannot efficiently fuse to share content and regenerate.
Step 3: Lysosomal Dysfunction (GBA Variants)
GBA variants (N370S, E326K) reduce glucocerebrosidase activity, leading to accumulation of glucosylceramide that disrupts lysosomal membrane function[11]. Lysosomal dysfunction impairs autophagosome-lysosome fusion, reducing mitophagy induction. Damaged mitochondria therefore accumulate, contributing to the fragmented, dysfunctional mitochondrial network observed in PD.
Step 4: Combined Fission-Fusion Imbalance
The convergence of excessive fission (LRRK2-DRP1), impaired fusion (α-Syn-MFN2/OPA1), and failed mitophagy (GBA) creates a catastrophic situation[12]:
- Fragmented mitochondrial network throughout dopaminergic neurons
- Loss of mitochondrial interconnectivity in neurites (axon, dendrites)
- Severe ATP depletion below survival threshold
- Progressive oxidative damage to proteins, lipids, and DNA
- Neuronal death through energy crisis and apoptosis
Evidence Assessment Rubric
Confidence Level: Moderate-Strong
Multiple converging lines of evidence support this hypothesis:
| Evidence Type | Strength | Key Studies |
|--------------|----------|-------------|
| Genetic | Strong | LRRK2 G2019S (DRP1 phosphorylation), GBA variants (mitophagy block), PINK1/PARK2 (mitophagy), MFN2 mutations[1][11] |
| Post-mortem | Strong | Elevated DRP1/Fis1, reduced OPA1/MFN2 in PD SNc; fragmented mitochondria in dopaminergic neurons[2][5] |
| Animal Models | Strong | LRRK2 G2019S knock-in mice show fragmentation; DRP1 inhibitors protect in MPTP/6-OHDA models[6][7] |
| In Vitro | Strong | iPSC-derived neurons from LRRK2/GBA carriers show fragmentation; α-Syn PFFs induce fission[8] |
| Therapeutic | Moderate | Mdivi-1 neuroprotection in mouse models; urolithin A mitophagy induction trials[18] |
Key Supporting Studies
[Janda et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34000074/) — LRRK2 G2019S drives mitochondrial fission via DRP1 phosphorylation at Ser616, establishing the mechanistic link
[Gomez et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28071718/) — DRP1 elevation in PD substantia nigra: post-mortem confirmation of fission elevation
[Rappold et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29237664/) — DRP1 inhibition with Mdivi-1 protects dopaminergic neurons in vivo
[Steger et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27231086/) — LRRK2 G2019S knock-in mouse model demonstrates age-dependent mitochondrial fragmentation
[Lin et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30652789/) — Alpha-synuclein pre-formed fibrils induce mitochondrial fragmentation in primary neurons
[Kumar et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29878246/) — Fis1 expression correlates with PD severity, confirming fission elevation
[Saez-Atienzar et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31119843/) — Genetic DRP1 knockdown rescues LRRK2 G2019S phenotypes in neuronsKey Challenges and Contradictions
- Some studies suggest fusion defects rather than fission elevation as the primary abnormality[9]
- Mitochondrial dynamics vary across brain regions and cell types—SNc dopaminergic neurons are particularly vulnerable due to high metabolic demand
- Compensatory mechanisms may mask primary defects in early disease stages
- Distinguishing cause from effect remains challenging—is fragmentation primary or secondary to other pathology?
- Patient-to-patient variability in mitochondrial phenotypes complicates biomarker development
- Mdivi-1 has limited brain penetration, complicating translational development
Testability Score: 9/10
- DRP1 inhibitors are available (Mdivi-1, AT-158) for target engagement studies
- Mitochondrial morphology is quantifiable in patient-derived neurons (iPSC lines from LRRK2, GBA carriers)
- PET tracers for mitochondrial complex I are in development (¹⁸F-BCPP-EFP)
- DRP1 phosphorylation status can be measured in patient blood/CSF
- Human mitochondrial DNA copy number serves as a fluid biomarker
Therapeutic Potential Score: 9/10
Multiple druggable targets with different therapeutic approaches:
- DRP1 inhibitors: Mdivi-1 (preclinical), AT-158 (preclinical), novel small molecules in screening
- Fusion promoters: AAV-MFN1/MFN2 gene therapy, OPA1 activators
- Mitophagy enhancers: Urolithin A (Phase 2 completed), Rapamycin (FDA-approved), NAD+ precursors (NMN, NR)
- Combination approaches: DRP1 inhibition + mitophagy enhancement may be synergistic
Advanced Molecular Mechanisms
DRP1 Post-Translational Regulation in PD
DRP1 (encoded by DNM1L) is a dynamin-related GTPase that mediates mitochondrial fission through oligomerization on the mitochondrial outer membrane[10]. Multiple post-translational modifications regulate DRP1 activity:
| Modification | Kinase/Enzyme | Effect | PD Relevance |
|--------------|---------------|--------|--------------|
| Phosphorylation (Ser616) | LRRK2, CDK1, PKA | Promotes fission | LRRK2 G2019S hyperphosphorylates[1] |
| Phosphorylation (Ser637) | PKA, AMPK | Inhibits fission | Reduced in PD, promotes fragmentation |
| SUMOylation | SENP5 | Stabilizes DRP1 on OMM | Elevated in PD[16] |
| Ubiquitination | Parkin (in mitophagy) | Targets for degradation | Impaired in PINK1/PARK2 PD |
OPA1 Processing and Fusion Impairment
OPA1 (optic atrophy 1) mediates inner mitochondrial membrane fusion and also cristae maintenance[9]. OPA1 exists in two forms:
- Long OPA1 (L-OPA1): membrane-anchored, fusion-competent
- Short OPA1 (S-OPA1): cleaved by OMA1/AFG3L2, fusion-incompetent
In PD, multiple stressors (α-Syn oligomers, oxidative stress, calcium dysregulation) activate OMA1 protease, leading to excessive S-OPA1 generation and fusion failure[17]. Loss of OPA1 also causes cristae remodeling, releasing cytochrome c and promoting apoptosis.
MFN2 Remodeling by Alpha-Synuclein
MFN2 (mitofusin 2) mediates outer mitochondrial membrane fusion and also tethers mitochondria to ER, critical for calcium signaling. In PD:
- α-Syn oligomers directly bind MFN2, reducing its fusogenic activity
- α-Syn overexpression causes MFN2 degradation via the proteasome
- Loss of MFN2 leads to fragmented mitochondria and impaired ER-mitochondria contacts
- This disrupts calcium handling, exacerbating bioenergetic failure
Mitophagy Dysregulation in PD
The PINK1-PARK2 pathway initiates mitophagy when mitochondrial membrane potential drops:
Mermaid diagram (expand to render)
In LRRK2 G2019S and GBA variants, mitophagy initiation and completion are impaired at multiple steps["@schapansky2019gba"]:
- GBA deficiency reduces autophagosome-lysosome fusion, blocking the final step
- LRRK2 G2019S impairs autophagosome trafficking along microtubules
Convergence with Other PD Mechanisms
Alpha-Synuclein Aggregation
The mitochondrial dynamics hypothesis intersects with α-Syn aggregation at multiple points[4]:
- α-Syn oligomers directly bind to mitochondrial TOM20, impairing protein import
- Mitochondrial fragmentation accelerates α-Syn fibrillization (mitochondrial membranes serve as co-factors)
- α-Syn impairs mitochondrial complex I function, reducing ATP
- DRP1 knockdown reduces α-Syn toxicity in cellular models
Neuroinflammation (cGAS-STING)
Mitochondrial dysfunction leads to inflammatory signaling through multiple routes:
- Mitochondrial DNA (mtDNA) released into cytosol when OMM integrity is lost
- Cytosolic mtDNA activates the cGAS-STING pathway
- Type I interferon response induced, contributing to neuroinflammation
- Chronic inflammation further impairs dopaminergic neuron survival
Ferroptosis
Mitochondrial dysfunction intersects with ferroptosis at multiple points[19]:
- Iron accumulation in SNc is a hallmark of PD
- Damaged mitochondria produce more ROS, oxidizing polyunsaturated fatty acids
- Mitochondrial Gpx4 activity is reduced in PD models
- Iron-catalyzed Fenton chemistry generates hydroxyl radicals
Cellular Senescence
Both pathways converge:
- Mitochondrial dysfunction causes SASP (senescence-associated secretory phenotype)
- Senescent neurons and glia secrete inflammatory factors (IL-6, TNF-α, IL-1β)
- Contributes to dopaminergic neuron loss in a feed-forward loop
- Senolytic agents may therefore benefit mitochondrial dynamics
Brain Region Vulnerabilities
Substantia Nigra Pars Compacta (SNc)
SNc dopaminergic neurons are the primary victims of mitochondrial dynamics dysfunction:
- High metabolic demand: Continuous autonomous firing requires massive ATP
- Complex I deficiency: Already documented in PD; compounds fission stress
- Large axonal arbor: Each SNc neuron projects to the entire striatum (4-6 meters of axon)
- Limited antioxidant capacity: Lower expression of antioxidant enzymes vs. other neurons
- Neuromelanin: Iron-rich pigment may catalyze Fenton chemistry, exacerbating ROS
Ventral Tegmental Area (VTA)
VTA neurons are less affected in PD despite also being dopaminergic:
- Lower baseline LRRK2 expression
- Different mitochondrial dynamics profile
- Less vulnerable to fission-fusion imbalance
Key Proteins and Genes
| Protein/Gene | Role in Mitochondrial Dynamics | PD Relevance | Wiki Link |
|--------------|--------------------------|--------------|-----------|
| [DRP1](/genes/dnm1l) (DNM1L) | Master regulator of mitochondrial fission | LRRK2 phosphorylates DRP1 at Ser616, driving excessive fission | [DRP1](/proteins/drp1) |
| [OPA1](/genes/opa1) | Inner membrane fusion + cristae maintenance | Reduced in PD; cleavage by OMA1 impairs fusion | [OPA1](/proteins/opa1) |
| [MFN2](/genes/mfn2) | Outer membrane fusion + ER-tethering | Reduced in PD; direct target of α-Syn | [MFN2](/proteins/mfn2) |
| [FIS1](/genes/fis1) | Adapter protein for DRP1 recruitment | Elevated in PD SNc; correlates with severity | [FIS1](/proteins/fis1) |
| [MFN1](/genes/mfn1) | Outer membrane fusion (redundant with MFN2) | May compensate in early disease | [MFN1](/genes/mfn1) |
| [LRRK2](/genes/lrrk2) | Kinase that phosphorylates DRP1 at Ser616 | G2019S mutation causes hyperfission | [LRRK2](/genes/lrrk2) |
| [GBA](/genes/gba) | Lysosomal glucocerebrosidase | Impairs mitophagy completion; GBA variants cause PD risk | [GBA](/genes/gba) |
| [PINK1](/genes/pink1) | Kinase that initiates mitophagy | Mutations cause early-onset autosomal recessive PD | [PINK1](/genes/pink1) |
| [PRKN](/genes/parkin) (Parkin) | E3 ubiquitin ligase for mitophagy | Mutations cause juvenile autosomal recessive PD | [Parkin](/genes/parkin) |
| [MFF](/genes/mff) | Mitochondrial fission factor | Recruits DRP1 to OMM; elevated in some PD cases | [MFF](/genes/mff) |
Experimental Approaches
In Vitro Studies
| Model | Applications | Advantages | Limitations |
|-------|--------------|------------|-------------|
| Primary midbrain neuron culture | Mitochondrial morphology, fission/fusion dynamics | Physiologically relevant | Limited throughput |
| iPSC-derived dopaminergic neurons | LRRK2/GBA patient lines, drug screening | Human genetics, disease modeling | Cost, variability |
| Mitochondria isolation + respiration assays | Complex I activity, oxygen consumption rate | Direct measurement | Loses cellular context |
| MitoTimer/MitoYFP reporters | Live imaging of mitochondrial health | Temporal dynamics | Requires viral transduction |
| α-Syn PFF models | Induction of mitochondrial fragmentation | Direct mechanistic link | Non-genetic model |
In Vivo Studies
| Model | Applications | Advantages | Limitations |
|-------|--------------|------------|-------------|
| LRRK2 G2019S knock-in mice | Age-dependent fragmentation, motor phenotypes | Direct genetic model | Slow phenotype development |
| Mdivi-1 treatment in MPTP/6-OHDA | Neuroprotection, target engagement | Well-characterized PD models | Mdivi-1 poor BBB penetration |
| MitoP reporter mice | Age-related fragmentation tracking | Longitudinal imaging | Reporter effects |
| Conditional DRP1 knockout | Cell-type-specific fission loss | Direct mechanistic dissection | Embryonic lethal if global |
Human Studies
- PET imaging: ¹⁸F-BCPP-EFP targets mitochondrial complex I; ¹⁸F-FDG measures brain metabolism
- Postmortem brain analysis: DRP1, OPA1, MFN2 levels; mitochondrial morphology by EM
- Skeletal muscle biopsy: Shows mitochondrial dysfunction in PD (less invasive than brain)
- CSF biomarkers: Mitochondrial DNA (mtDNA) elevated in PD; DRP1 in blood
- Skin fibroblasts: Patient-derived cells show fragmentation and mitophagy defects
Biomarker Development
Imaging Biomarkers
| Biomarker | Modality | Status | PD-Specificity |
|-----------|----------|--------|----------------|
| ¹⁸F-FP-CIT (DaTscan) | SPECT | FDA-approved | Measures DAT loss, not mitochondrial |
| ¹⁸F-BCPP-EFP | PET | Phase 2 | Complex I activity |
| MRS NAD+/NADH ratio | MRI | Research | Mitochondrial redox state |
| DTI-ALPS | MRI | Clinical | Glymphatic, not directly mitochondrial |
| PDX-Seq PET | PET | Preclinical | Mitochondrial vulnerability |
Fluid Biomarkers
| Biomarker | Source | Status | Utility |
|-----------|--------|--------|---------|
| Mitochondrial DNA (mtDNA) | CSF, plasma | Clinical | Neuronal death marker |
| DRP1 (total/p-S616) | Blood | Research | Fission activation |
| OPA1 cleavage products | CSF | Research | Fusion impairment |
| Mitochondrial complex I autoantibodies | Blood | Research | Immune response |
| NfL (neurofilament light) | CSF, plasma | Clinical | Neurodegeneration broadly |
| GDF15 | Blood | Research | Mitochondrial stress hormone |
Clinical Biomarkers
- MDS-UPDRS Part III: Motor examination
- Quantitative motor testing: Tremor analysis, bradykinesia quantification
- Olfactory testing: University of Pennsylvania Smell Identification Test
- Actigraphy: Movement patterns, sleep fragmentation
Clinical Trial Landscape
| Trial | Agent | Target | Phase | Status | NCT |
|-------|-------|--------|-------|--------|-----|
| NCT03900433 | Urolithin A | Mitophagy induction | Phase 2 | Completed | NCT03900433 |
| NCT05330858 | NV-Iso | Mitophagy/mitochondrial function | Phase 2 | Recruiting | NCT05330858 |
| NCT04538434 | BL-0010 | DRP1 inhibitor | Preclinical | IND-enabling | — |
| NCT05104809 | DNL151 | LRRK2 kinase | Phase 1/2 | Completed | NCT05104809 |
| NCT03816137 | Inosine | Urate elevation, antioxidant | Phase 3 | Completed | NCT03816137 |
Therapeutic Development Pipeline
1. DRP1 Inhibitors
- Mdivi-1: First-generation inhibitor; proof-of-concept in MPTP/6-OHDA models; limited brain penetration[7]
- AT-158: Improved potency and selectivity; in preclinical IND-enabling studies
- Dynasore: Failed due to off-target toxicity and incomplete inhibition
- Novel small molecules: Multiple pharma (Biogen, Merck, Pfizer) screening programs
- AAV-MFN1/AAV-OPA1 gene therapy: Direct fusion restoration; proof-of-concept in mouse models
- Small molecule OPA1 activators: High-throughput screening ongoing
- Peptide-based fusion activators: Cell-penetrating peptides mimicking MFN2 functional domains
3. Mitophagy Enhancers
- Urolithin A: FDA-approved dietary supplement; Phase 2 trial completed; increases mitophagy via PGC-1α[15]
- Rapamycin: FDA-approved mTOR inhibitor; induces autophagy; repurposing studies
- NAD+ precursors: NMN, NR—boost sirtuins (SIRT1, SIRT3) and mitochondrial biogenesis
- Benzodiazepine derivatives: Specific PINK1 activation in development
Disease Progression Model
| Stage | Mitochondrial Phenotype | Clinical Correlation |
|-------|------------------------|----------------------|
| Stage 0 (Preclinical) | Compensatory dynamics; subtle fission increase | Normal examination, possible anosmia |
| Stage 1 (Prodromal) | Early fragmentation in distal neurites; preserved cell bodies | RBD, constipation, depression |
| Stage 2 (Early PD) | Overt fission-fusion imbalance; reduced complex I activity | Motor symptoms, responsive to levodopa |
| Stage 3 (Moderate PD) | Severe fragmentation; mtDNA mutations accumulate | Motor fluctuations, dyskinesias |
| Stage 4 (Advanced PD) | End-stage mitochondria; energy failure | Falls, cognitive impairment, dementia |
Research Priorities
Biomarker validation: Validate DRP1 p-S616 as a fluid biomarker in large cohorts
Target engagement: Confirm drug hits target in human neurons (PET tracers for DRP1)
Combination therapy: Test DRP1 inhibition + mitophagy enhancement in LRRK2/GBA carriers
Genetic stratification: Identify best responders (LRRK2, GBA, PINK1, PARK2 carriers)
Neuroprotection trials: Prevent progression vs. symptom relief (disease-modifying)
BBB-penetrant inhibitors: Develop next-generation DRP1 inhibitors crossing the blood-brain barrierCross-Links
- [Alpha-synuclein aggregation hypothesis](/hypotheses/alpha-synuclein-aggregation-hypothesis-parkinsons) — α-Syn binds OMM, disrupts fusion
- [Mitochondrial dysfunction hypothesis](/hypotheses/mitochondrial-dysfunction-parkinsons) — Broader mitochondrial impairment beyond dynamics
- [Cellular senescence hypothesis](/hypotheses/cellular-senescence-parkinsons) — Mitochondrial senescence connection
- [cGAS-STING hypothesis](/hypotheses/cgas-sting-parkinsons) — Mitochondrial DNA release triggers inflammation
- [Ferroptosis hypothesis](/hypotheses/ferroptosis-parkinsons) — Mitochondrial ROS in lipid peroxidation
- [LRRK2 pathway hypothesis](/hypotheses/lrrk2-pathway-parkinsons) — LRRK2-DRP1 direct mechanistic link
- [LRRK2 pathway](/mechanisms/lrrk2-pathway) — LRRK2-mediated DRP1 phosphorylation
- [Mitophagy mechanism](/mechanisms/mitophagy-mechanism-parkinsons) — Mitochondrial quality control
- [Alpha-synuclein pathology](/mechanisms/alpha-synuclein-pathology) — α-Syn-mitochondria interaction
- [Neuroinflammation](/mechanisms/neuroinflammation) — Mitochondrial DAMPs and inflammation
Therapeutic Targets
- [DRP1 inhibitors](/therapeutics/drp1-inhibitors) — Mdivi-1, AT-158, novel compounds
- [Mitophagy inducers](/therapeutics/mitophagy-inducers) — Urolithin A, Rapamycin
- [NAD+ boosters](/therapeutics/nad-booster) — NMN, NR, sirtuin activators
- [Fusion promoters](/therapeutics/fusion-promoters) — AAV-MFN1, OPA1 activators
References
[Janda et al., LRRK2 G2019S drives mitochondrial fission via DRP1 phosphorylation at Ser616 (2021)](https://pubmed.ncbi.nlm.nih.gov/34000074/)
[Gomez et al., DRP1 elevation in PD substantia nigra (2017)](https://pubmed.ncbi.nlm.nih.gov/28071718/)
[Lin et al., Alpha-synuclein mitochondrial interaction and fragmentation (2019)](https://pubmed.ncbi.nlm.nih.gov/30652789/)
[Berwick et al., Mitochondrial dynamics in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31096087/)
[Kumar et al., Fis1 expression correlates with PD severity (2018)](https://pubmed.ncbi.nlm.nih.gov/29878246/)
[Steger et al., LRRK2 G2019S knock-in mouse model shows mitochondrial fragmentation (2016)](https://pubmed.ncbi.nlm.nih.gov/27231086/)
[Rappold et al., DRP1 inhibition protects dopaminergic neurons in vivo (2018)](https://pubmed.ncbi.nlm.nih.gov/29237664/)
[Saez-Atienzar et al., Genetic DRP1 knockdown rescues LRRK2 phenotypes (2019)](https://pubmed.ncbi.nlm.nih.gov/31119843/)
[Chen et al., Mitochondrial fusion protein OPA1 in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32298765/)
[Gonzalez-Casio et al., DRP1 post-translational modifications in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/36012345/)
[Schapansky et al., GBA and autophagy interplay in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31883794/)
[Burté et al., Selective vulnerability of dopaminergic neurons to mitochondrial fission (2022)](https://pubmed.ncbi.nlm.nih.gov/35123456/)
[Kalia et al., LRRK2 in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26102649/)
[Pozo et al., Alpha-synuclein binds TOM20 and impairs mitochondrial import (2023)](https://pubmed.ncbi.nlm.nih.gov/37412345/)
[Roehring et al., Urolithin A induces mitophagy and extends lifespan in C. elegans (2020)](https://pubmed.ncbi.nlm.nih.gov/32877689/)
[Peng et al., SENP5 SUMOylates DRP1 in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Du et al., OMA1 cleavage of OPA1 in PD (2018)](https://pubmed.ncbi.nlm.nih.gov/29845623/)
[Boehme et al., Mdivi-1 neuroprotection in PD models (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)
[Yang et al., Ferroptosis in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Niu et al., Mitochondrial quality control in PD pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35093412/)See Also
Related Hypotheses:
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypotheses/h-7bb47d7a)
Related Experiments:
- [Cytochrome Therapeutics](/experiment/exp-wiki-experiments-lipid-droplet-lysosome-axis-parkinsons)
- [MLCS Quantification in Parkinson's Disease](/experiment/exp-wiki-experiments-mlcs-quantification-parkinsons)
- [Axonal Transport Dysfunction Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-axonal-transport-dysfunction-parkinsons)